» Articles » PMID: 35173353

Global DNA Methylation and Increased DNMT3A Expression in Multiple Myeloma Patients

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The aim of this study was to compare the expression profile of selected DNA methyltransferases and global DNA methylation status in patients with different phases of multiple myeloma (MM) . For the analysis, different cellular populations including unsorted myeloma cells and a set of plasma cells purified by relevant antibodies were used. Consequently, laboratory data were compared to patients' clinical data.

Patients And Methods: For the analysis, unsorted bone marrow cell population of 44 MM patients (30 newly diagnosed, 9 relapsed and 5 patients in remission) and a set of 8 patients' samples of sorted plasma cells were used. We used commercially available RNA isolated from BM of 3 healthy individuals as control samples. Expression analysis of three DNA methyltransferases - DNMT1, DNMT3A, and DNMT3B was performed by quantitative RT-PCR and the patient global DNA methylation profiles were detected by colorimetric assay.

Results: Unchanged DNMT1 expression was detected in the selected cohort of patients. Normalized DNMT3A gene expression was globally higher in comparison with controls in unsorted and sorted cell populations. Low (0.08-1.81%) global DNA methylation status in unsorted samples of multiple myeloma patients did not correlate either with expression profiles of monitored DNA methyltransferases or with the stages of MM based on Durie-Salmon and International Staging System.

Conclusion: This is the first comparative study between DNA methyltransferases expression profiles and global DNA methylation status in different phases of multiple myeloma patients. No significant correlation between the level of global methylation and the clinical stage of the unsorted cell population of patients with multiple myeloma was registered. Overexpression of the DNMT3A gene occurred in both sorted and unsorted cell populations of patients with multiple myeloma. This fact highlights the DNMT3A as a potential marker of multiple myeloma tumor progression. Moreover, we demonstrated comparable results in the expression of DNA methyltransferases in both sorted and unsorted cell populations. This is a promising result from the methodical point of view because when compared to samples of unsorted multiple myeloma cells, samples of sorted cells bring reduction of the number of possible analyses performed.

Citing Articles

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

Zhao A, Zhou H, Yang J, Li M, Niu T Signal Transduct Target Ther. 2023; 8(1):71.

PMID: 36797244 PMC: 9935927. DOI: 10.1038/s41392-023-01342-6.


Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?.

Muylaert C, Van Hemelrijck L, Maes A, de Veirman K, Menu E, Vanderkerken K Front Oncol. 2022; 12:979569.

PMID: 36059621 PMC: 9434119. DOI: 10.3389/fonc.2022.979569.

References
1.
Rollig C, Illmer T . The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev. 2009; 35(5):425-30. DOI: 10.1016/j.ctrv.2009.04.007. View

2.
Bringhen S, Mateos M, Zweegman S, Larocca A, Falcone A, Oriol A . Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98(6):980-7. PMC: 3669456. DOI: 10.3324/haematol.2012.075051. View

3.
Neuse C, Lomas O, Schliemann C, Shen Y, Manier S, Bustoros M . Genome instability in multiple myeloma. Leukemia. 2020; 34(11):2887-2897. DOI: 10.1038/s41375-020-0921-y. View

4.
Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta J, Cavo M . Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013; 31(26):3279-87. DOI: 10.1200/JCO.2012.48.4626. View

5.
Manier S, Salem K, Park J, Landau D, Getz G, Ghobrial I . Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2016; 14(2):100-113. DOI: 10.1038/nrclinonc.2016.122. View